MedPath

Gefitinib

Generic Name
Gefitinib
Brand Names
Iressa, Gefitinib Mylan
Drug Type
Small Molecule
Chemical Formula
C22H24ClFN4O3
CAS Number
184475-35-2
Unique Ingredient Identifier
S65743JHBS

Overview

Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

Indication

For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

Associated Conditions

  • Metastatic Non-Small Cell Lung Cancer

Research Report

Published: Jul 17, 2025

Gefitinib (DB00317): A Comprehensive Monograph on its Pharmacology, Clinical Utility, and Evolving Role in Precision Oncology

Executive Summary

Gefitinib, marketed under the brand name Iressa®, is an orally active, small molecule therapeutic that represents a foundational achievement in the field of precision oncology.[1] As a first-generation inhibitor of the Epidermal Growth Factor Receptor (EGFR) tyrosine kinase, its development and clinical application have profoundly shaped the modern approach to treating non-small cell lung cancer (NSCLC).[1] The core mechanism of Gefitinib involves the reversible and competitive inhibition of the adenosine triphosphate (ATP) binding site within the EGFR's intracellular kinase domain. This action is particularly potent against tumors driven by specific "activating" mutations, namely exon 19 deletions and the L858R substitution in exon 21, for which Gefitinib demonstrates a significantly higher binding affinity compared to the wild-type receptor.[1]

The primary clinical application of Gefitinib is as a first-line monotherapy for patients with metastatic NSCLC whose tumors harbor these sensitizing EGFR mutations.[4] This targeted indication was definitively established by the landmark Iressa Pan-Asia Study (IPASS), which demonstrated superior progression-free survival (PFS) for Gefitinib over standard chemotherapy in the EGFR-mutated patient population, thereby cementing the role of EGFR mutation status as a critical predictive biomarker.[8] However, the initial efficacy of Gefitinib is invariably limited by the emergence of acquired resistance. The most common resistance mechanism is the development of a secondary "gatekeeper" mutation, T790M, which restores the kinase's affinity for ATP and renders the tumor insensitive to the drug.[1]

Continue reading the full research report

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
2005/09/15
Phase 2
Completed
2005/09/15
Phase 2
Terminated
Groupe Oncologie Radiotherapie Tete et Cou
2005/08/30
Phase 2
Completed
2005/08/16
Phase 2
Completed
2005/08/09
Phase 1
Completed
2005/08/04
Phase 2
Completed
2005/06/09
Phase 1
Completed
2005/03/04
Not Applicable
Terminated
2005/02/08
Phase 2
Completed
2005/01/10
Phase 2
Completed

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

View More TGA Approvals

Sign in to access additional TGA-approved drug information with detailed regulatory data.

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

View More Health Canada Approvals

Sign in to access additional Health Canada approved drug information with detailed regulatory data.

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

View More CIMA AEMPS Approvals

Sign in to access additional CIMA AEMPS approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

View More Philippines FDA Approvals

Sign in to access additional Philippines FDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

View More Saudi SFDA Approvals

Sign in to access additional Saudi SFDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

View More Malaysia NPRA Approvals

Sign in to access additional Malaysia NPRA approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

View More UK EMC Drug Information

Sign in to access additional UK EMC drug information with detailed pharmaceutical data.

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.